7% growth for Japanese Rx market in 2011 despite quake
This article was originally published in Scrip
Japan's prescription drug market grew by a solid 7% to ¥9,481.6 billion ($120.5 billion) in calendar 2011 despite the March earthquake, tsunami and nuclear crisis, driven in large part by big increases in sales in the oncology, diabetes and vaccines sectors.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.